Litcius/Paper detail

Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors

Hanjie Mo, Catherine Renna, Halle C. F. Moore, Jame Abraham, Megan Kruse, Alberto J. Montero, Susan B. LeGrand, Lu Wang, G. Thomas Budd

2021Clinical Breast Cancer33 citationsDOI

Topics & Concepts

MedicineExemestaneEverolimusAromatase inhibitorInternal medicineMetastatic breast cancerBreast cancerOncologyProgression-free survivalPalbociclibRetrospective cohort studyCancerSurgeryOverall survivalAromataseAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyEstrogen and related hormone effects
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors | Litcius